Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.

Oral Mucositis (Ulcerative) Due to Radiation Clinical Trial

Official title:

Clinical Study Evaluating the Efficacy and Safety of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06354712
• Other study ID #: 2024-45
• Status: Recruiting
• Phase: Phase 2
• Start date: April 4, 2024
• Est. completion date: March 1, 2025

Study information

• Verified date: April 2024
• Source: Mansoura University
• Contact: Mohamed Shams, Professor
• Phone: +201556300563
• Email: mshamspharma[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, randomized, controlled, parallel clinical trial will be conducted at Clinical Oncology and Nuclear Medicine Center at Mansoura University Hospital to assess the efficacy of N-acetylcysteine in the prevention of radiotherapy induced oral mucositis in Head and Neck cancer patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: March 1, 2025
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Adults >18 years diagnosed with squamous cell carcinoma of the head and neck scheduled to receive curative radiotherapy (Primary or postoperative) of at least 50 Gy with or without concurrent chemotherapy.

2. Individuals with healthy mucosa.

3. Adequate bone marrow function (Hemoglobin level =10 g/dL, platelet count =75 × 103/microliter, and absolute neutrophil count =1.5 × 103/microliter).

4. Patients with ECOG performance =2

Exclusion Criteria:

1. History of chemotherapy or radiotherapy.

2. Signs of systemic infections.

3. Pregnant and lactating women.

4. Individuals receiving systemic analgesics.

5. Liver disorders and renal failure with eGFR <30 ml/min/1.73m2 (by the MDRD equation).

6. Inability to follow instructions and complete the questionnaires.

Related Conditions & MeSH terms

• Head and Neck Neoplasms
• Mucositis
• Oral Mucositis (Ulcerative) Due to Radiation
• Stomatitis

Intervention

Drug:
• N-Acetyl-Cysteine with Institutional standard care
A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
• Institutional standard care
Benzydamine Mouthwash

Locations

Country	Name	City	State
Egypt	Clinical Oncology and Nuclear Medicine of Mansoura University Hospital	Mansoura

Sponsors (1)

Lead Sponsor	Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of oral mucositis with grade = 2 assessed weekly by World Health Organization scale for Oral Mucositis.	Difference between the two arms regarding incidence of grade = 2 according to World Health Organization scale for Oral Mucositis.	8 weeks
Secondary	Time to develop oral mucositis with grade = 2.	Difference between the two arms regarding time to develop oral mucositis with grade = 2 according to WHO scale for oral mucositis.; World Health Organization scale for oral mucositis; Grade 0: no oral mucositis; Grade 1: erythema and soreness; Grade 2: ulcers, able to eat solids; Grade 3: ulcers, requires liquid diet; Grade 4: ulcers, alimentation not possible (due to mucositis).	8 weeks
Secondary	Duration of oral mucositis with grade = 2.	Difference between the two arms regarding duration of oral mucositis with grade = 2 according to WHO scale for oral mucositis.	8 weeks
Secondary	Pain assessed by Visual Analog Scale (VAS).	The pain VAS is a unidimensional measure of pain intensity, used to record patients' pain progression. The most simple VAS is a straight horizontal line of fixed length usually 100 mm. The ends are defined as the extreme limits of the parameter to be measured (pain) orientated from the left (worst) to the right (best).; we will allocate this scale in comparing pain severity between the two arms.	8 weeks
Secondary	Functional oral intake scale	TUBE DEPENDENT (levels 1-3); No oral intake; Tube dependent with minimal/inconsistent oral intake 3 Tube supplements with consistent oral intake; TOTAL ORAL INTAKE (levels 4-7) 4. Total oral intake of a single consistency 5. Total oral intake of multiple consistencies requiring special preparation 6. Total oral intake with no special preparation, but must avoid specific foods or liquid items 7. Total oral intake with no restrictions	8 weeks
Secondary	Patient's quality of life assessed by Functional Assessment of Cancer Therapy in Head and Neck Cancer (FACT-H&N) version 4	A questionnaire filled by head and neck cancer patient to assess the quality of life.; H&N1 I am able to eat the foods that I like H&N2 My mouth is dry H&N3 I have trouble breathing H&N4 My voice has its usual quality and strength H&N5 I am able to eat as much food as I want H&N6 I am unhappy with how my face and neck look H&N7 I can swallow naturally and easily H&N8 I smoke cigarettes or other tobacco products H&N9 I drink alcohol (e.g. beer, wine, etc.) H&N10 I am able to communicate with others H&N11 I can eat solid foods H&N12 I have pain in my mouth, throat or neck; Scoring:Not at all (0) A little bit (1) Somewhat (2) Quite a bit (3) Very much(4)	8 weeks